Respirix Status
The company raised $1.5 million of convertible debt financing from Synergy Ventures, Signatures Capital and Level Ventures on January 12, 2017.
Developer of a portable device designed to monitor cardiac health. The company provides's portable device offers proprietary insights into the pulmonary vasculature non-invasively and aims to address both at-home monitoring and critical care applications in categories such as heart failure and hemodynamics, enabling patients to obtain reproducible measurements independent of interpatient variability with little to no subject training required.
Year Founded
2015
Employees
5
General Information
-
Website
-
Business Status
Clinical Trials - Phase 1
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Respirix News and Updates
7 cardiology startups you need to know
Medical Design & Outsourcing | April 24, 2023
22 MedTech Innovator all-stars will pitch at DeviceTalks Boston
Mass Device | April 18, 2023
Stanford alumni founders tackle COVID-19 coronavirus with StartX ...
Silicon Valley Business Journal | March 19, 2020
Respirix for Non-Invasive Cardiopulmonary Monitoring: Interview ...
Medgadget | March 17, 2020
Respirix's Verticals
Respirix Primary Industry Sector / Group / Code
Respirix's Trends
Headquarters
-
HQ Address Line 1101 Mississippi Street
-
HQ Address Line 2Suite 400
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94107
-
HQ CountryUnited States
Respirix's Keywords
mood_badFeed is empty.
Add a review